# Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

> **NCT05839119** · PHASE1 · TERMINATED · sponsor: **Brown University** · enrollment: 2 (actual)

## Conditions studied

- Urothelial Carcinoma Bladder
- Androgen Receptor Positive

## Interventions

- **DRUG:** Degarelix
- **COMBINATION_PRODUCT:** Gemcitabine/Cisplatin

## Key facts

- **NCT ID:** NCT05839119
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-02
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-10-17
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Principal Investigator left institution
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05839119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05839119, "Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05839119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*